JUN 21, 2018 10:30 AM PDT

Setting Up Next-Generation Sequencing for the Needs of Routine Molecular Diagnostics With a Focus on the Suitability of the GeneReader NGS System for Lung Cancer Patients

SPONSORED BY: QIAGEN
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Head of the Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Head of the Human Biobank Unit, Pasteur Hospital
    Biography
      Paul Hofman obtained his MD degree in 1989 at the University Côte d'Azur (Nice, France) and his PhD in 1994 at the University of Montpellier I (Montpellier, France). Having completed research fellowships in the Department of Pathology at the Brigham and Women's Hospital (Harvard Medical School, Boston, USA) and at the Max Planck Institut (Tubingen, Germany), he became full Professor of Pathology and Head of a research team at the Inserm 1081/UMR CNRS 7284 (IRCAN; www.ircan.org), located at the Comprehensive Cancer Center Antoine Lacassagne (Nice) in 1995. His group's research focus is lung cancer pathophysiology and the discovery of predictive and prognostic biomarkers. Paul is also head of the Hospital-related Biobank (BB-0033-00025) and of the Laboratory of Clinical and Experimental Pathology at Nice Hospital as well as being Director of the OncoAge Consortium in France (www.oncoage.org). He has published more than 450 peer review publications.

    Abstract:

    The introduction of targeted therapies into the clinical management of lung adenocarcinoma has had a massive impact on patient care. Multiple driver mutations are now druggable and treatments differ depending on the mutational pattern of each patient with advanced lung adenocarcinoma. Consequently, mutational analysis is critical for treatment decisions in clinical routine practice. While several techniques have been developed and introduced into clinical care over the past few years, next-generation sequencing (NGS) has evolved to become the new standard in molecular diagnostics for most institutions. Thus, the development of targeted sequencing panels, which only cover specific and relevant mutations, make NGS affordable and suitable for high-throughput processing. There is no consensus system for individual sample tracking and the storage of meta information which is therefore required to be set up in each diagnostic laboratory individually. Additionally, setting up a NGS workflow requires well-trained personal, complex workflows and the need for specialized bioinformatics to analyze and interpret the results. Two different sequencing techniques were established initially for NGS in clinics, the Ion Personal Genome Machine (PGM) and Illumina sequencing. While both systems are based on fundamentally different sequencing principles, their purpose for clinical mutation analysis is quite similar. However, both systems require each diagnostic laboratory to develop their own workflow, leading to a plethora of “homebrew” solutions as different devices for sample preparation can be integrated in the respective workflows

    QIAGEN developed a novel sequencing system, the GeneReader, specifically designed for the needs of routine molecular diagnostics. In contrast to the existing solutions, the GeneReader system provides a complete workflow from sample preparation to data analysis. This reduced hands-on time during sample preparation, increased sample traceability and reproducibility address many of the issues of “homebrew” NGS solutions. Bioinformatic analysis is well integrated into the workflow and automated to strongly improve the quality and efficacy. The GeneReader can easily be installed and integrated into a routine pathology laboratory. Only limited training of the technical personnel is necessary. The high traceability is a strong advantage for daily routine sequencing and maybe very helpful for easily getting an accreditation according to the ISO 15189 norm. 

    Here we will present the main characteristics of the GeneReader NGS system and the potential for using this system in daily practice. We demonstrate the suitability of the GeneReader NGS system in routine in a clinical and molecular pathology laboratory setting.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    Loading Comments...
    Show Resources